LCMC3 primary analysis: Neoadjuvant atezolizumab in NSCLC

(2:59)

Dr. Merritt on the Prognostic Value of SUVmax Change in the LCMC3 Study

(5:50)

LCMC3: adjuvant and neoadjuvant atezolizumab in early-stage NCSLC

(1:39)

Treating Unresectable Stage III NSCLC: A Focus on Stage IIIC Disease

(5:54)

LCC Treatment of Resectable Stage III NSCLC

(5:40)

Treating Unresectable Stage III NSCLC: A Focus on Stage IIIA Disease

(5:54)

Advances in Immunotherapy \u0026 Resectable Non-Small Cell Lung Cancer

(45:21)

LCC Treatment of Unresectable Stage III NSCLC

(8:41)

T-Cell dynamics in response to neoadjuvant atezolizumab in early NSCLC

(2:3)

Checkmate 816: Neoadjuvant Nivolumab + Chemotherapy for NSCLC - OncTalk Lung 2023

(3:25)

Advances in the management of Thoracic Malignancies 3 Sep 2021 day 1 part 1

(1:39:44)

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLC

(7:)

Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC

(4:5)

abc Oncology Course 2021 - Lung Cancer Module - Session 1

(2:25:43)

Clinical trials of neoadjuvant targeted therapy in resectable NSCLC

(2:28)

What is multi-focal lung cancer?

(2:49)

Has Immunotherapy Brought Us to an Inflection Point in the Management of Stage I-III NSCLC?

(1:8:)

The Role of Surgery in NSCLC Following PACIFIC Trial

(6:41)

Is adjuvant immunotherapy necessary in non-small cell lung cancer?

(1:52)